NEW YORK (GenomeWeb News) — Rosetta Genomics today said that a Columbia University Medical Center lab will validate the company’s microRNA-based diagnostics program for Cancer of Unknown Primary.
The agreement calls for the company to provide the school’s Clinical Laboratory Improvement Amendments-certified lab with its protocol for diagnosing the primary origin of metastatic cancers, which will then be tested and validated using blinded samples provided by the medical center.
The alliance is Rosetta Genomics' first agreement that aims to clinically validate one of its cancer diagnostics. The company is developing several diagnostics at its R&D facilities in Israel and the United States.
The CUP diagnostic, currently in the final stages of development, is designed to help clinicians identify the origin of tumors that have metastasized throughout the body.